Pharmaceutical & Biotech
One-Time Gain Helps to Boost Abbott's Profit 53% by Offsetting Lower Sales
Abbott Laboratories (NYSE:ABT) (Abbott Park, Illinois) has announced that it posted a first-quarter 2009 profit of $1.44 billion, up 53.4% compared with $938 million year over year. ...
Released Thursday, April 16, 2009
Researched by Industrial Info Resources (Sugar Land, Texas)--Abbott Laboratories (NYSE:ABT) (Abbott Park, Illinois) has announced that it posted a first-quarter 2009 profit of $1.44 billion, up 53.4% compared with $938 million year over year. The increase is attributed to a one-time gain of $505 million after taxes related to a partnership with Japan's Takeda Pharmaceutical Company (TYO:4502) (Osaka).
Sales for the quarter totaled $6.72 billion, down 0.7% compared with $6.78 billion in the same period last year. Sales of Abbott's drug Humira, approved to treat rheumatoid arthritis, psoriatic arthritis, Crohn's disease and other conditions, rose 16.7% to $1.02 billion. However, sales of Depakote, used to treat seizure disorders and the manic phase of bipolar disorder, dropped 64.5% to $129 million as a result of generic-drug competition.
Abbott's smaller business units Nutritional Products and Medical Products posted sales gains of 6.4% and 42.7%, respectively. The large increase in Medical Products is attributed to coronary stent sales, which jumped 112.4% to $402 million for the quarter. The Diagnostics business unit, experienced a 1.8% decline in sales.
Industrial Info's 2009 Pharmaceutical & Biotech Industry Outlook packages useful, timely and essential information and statistics into one easy-to-use format. Features include upcoming trends, vital plant and project statistics, as well as a capital and maintenance spending analysis derived from our information databases. The Pharmaceutical Tracker - Online Database contains operational plant data, as well as sites under development in the Pharmaceutical and Biotech Industry. Individual active capital and maintenance spending reports spanning North America are also covered within the Pharmaceutical Tracker.
Industrial Info is tracking 12 active Abbott projects in the U.S. worth $172 million combined. The projects range from $1 million maintenance shutdowns to a $150 million grassroot research center.
Industrial Info Resources (IIR) is a marketing information service specializing in industrial process, energy and financial related markets with products and services ranging from industry news, analytics, forecasting, plant and project databases, as well as multimedia services.
Want More IIR News Intelligence?
Make us a Preferred Source on Google to see more of us when you search.
Add Us On GoogleAsk Us
Have a question for our staff?
Submit a question and one of our experts will be happy to assist you.
Forecasts & Analytical Solutions
Where global project and asset data meets advanced analytics for smarter market sizing and forecasting.
Explore Our SolutionsRelated Articles
-
Eli Lilly Advances U.S. Manufacturing BuildoutSeptember 24, 2026
-
U.S. States Planning the Most Industrial Spending in 2027September 08, 2026
-
U.S. Megaprojects to Watch for in 2027September 01, 2026
-
GLP-1 Drugs Drive Pharma Construction WaveAugust 27, 2026
-
El Niño Shapes North America Fall, Winter OutlookAugust 27, 2026
PECWeb Global Market Intelligence Platform
Identify opportunities, anticipate change, and execute with confidence. PECWeb connects the industrial intelligence you need, from projects and assets to operational events, all in one platform.
Discover PecwebIndustry Intel
-
North America Refining 2026: New Pipelines to PADD 5Podcast Episode / Oct 2, 2026
-
Biomanufacturing Onshoring 2026: GLP-1 Drives CapexPodcast Episode / Oct 2, 2026
-
2026 US Data Center Outlook: Power, Land & CoolingPodcast Episode / Sep 18, 2026
-
2026 Global Power Demand Outlook: Gas, Nuclear & RenewablesPodcast Episode / Sep 18, 2026
-
2026 Oil & Gas CapEx Outlook: Middle East, LNG & PermianPodcast Episode / Sep 4, 2026